Peptoniphilus asaccharolyticus

(aka Peptostreptococcus asaccharolyticus)

Bacteria
General | Carbohydrate O/F | Substrate utilisation | Enzymes | Metabolites | Antibiotics

Overview

  • Peptoniphilus asaccharolyticus, (aka Peptostreptococcus asaccharolyticus), is a Gram-positive, non-spore-forming, strictly anaerobic, non-motile, coccus bacterium. It has been detected in at least 8 gut microbiome compilation studies or metastudies. The DNA G+C content is 31-32%. Peptoniphilus asaccharolyticus is probably a common, although minor, coloniser of the gut. (Ezaki1983; Ezaki2001; Ezaki2011eBergey; Murdoch1998a)



  • This organism has been recovered from human faeces, and clinical sources (vaginal discharge and various abscesses). The risk classification (www.baua.de) for this organism is 2, i.e., risk of individual infection, but low risk of spread. It is an opportunistic pathogen. Is a known gut commensal.
    • GENERAL CHARACTERISTICS (Ezaki1983); (Ezaki2001); (Ezaki2011eBergey); (Murdoch1998a);
    Character Response
  • Substrates hydrolysed or digested:
  • hippurate;
  • 🌡
  • Temperature tolerance:
  • Grows optimally at 37℃.
    • SPECIAL FEATURES (Ezaki1983); (Ezaki2001); (Ezaki2011eBergey); (Murdoch1998a);
    Character Response
  • ✓
  • Metabolites produced:
  • butyrate; indole (most strains);
  • ✗
  • VP test:
  • not active
  • ✗
  • Nitrate:
  • not reduced
    • RESPONSE TO ANTIBIOTICS (Goldstein2013); (Tyrrell2012); (Snydman2008); (Goldstein2008); (Goldstein2006a); (Goldstein2006b); (Goldstein2006c); (Goldstein2005); (Citron2003); (Goldstein2003a); (Goldstein2000); (Goldstein2000a); (Goldstein1999); (Goldstein1999a); (Goldstein1999b); (Goldstein1991); (Murdoch1998a);
    Class Active Resistant
  • Penicillins:
  • amoxicillin; amoxicillin-clavulanic acid; ampicillin; ampicillin-sulbactam; doripenem; ertapenem; imipenem; meropenem; penicillin; penicillin G; piperacillin-tazobactam; ticarcillin-clavulanic acid;
  • Cephalosporins:
  • cefepime; cefoperazone; cefotaxime; cefotetan; cefoxitin; cefuroxime; moxalactam;
  • Macrolides:
  • clarithromycin; pristinamycin; quinupristin-dalfopristin; telithromycin;
  • Tetracyclines:
  • doxycycline; minocycline; tigecycline;
  • Quinolines:
  • gatifloxacin; gemifloxacin; moxifloxacin; sparfloxacin; trovafloxacin;
  • Polypep/ketides:
  • bacitracin;
  • Heterocycles:
  • chloramphenicol; metronidazole;
  • Vancomycins:
  • vancomycin; dalbavancin; teicoplanin;
  • Miscellaneous antibiotics:
  • daptomycin; linezolid; pristinamycin; ranbezolid; telithromycin;

  • Distaso, A (1912). Contribution à l'étude sur l'intoxication intestinale. Zbl. Bakt. Parasit. 62: 433-468.

    • Details

    GENERAL
    Lineage Physiology General Growth Tolerances Hydrol./digest./degr.
    Phylum:  Firmicutes Class:  Tissierellia Order:  Tissierellales Family:  Peptoniphilaceae Genus:  Peptoniphilus Alt. name:  Peptostreptococcus asaccharolyticus Gram stain:  + O2 Relation.:  strictly anaerobic Spore:  No spore Motility:  Sessile Morphology:  Coccus
    Health:  Unknown
    Source:  human faeces, and clinical sources (vaginal discharge and various abscesses)
    DNA G+C(%):  31-32
    Opt. T:  37℃
    		Urea:  neg Hippurate:  +
    CARBOHYDRATE ACID FORMATION
    Monosaccharide O/F Oligosaccharide O/F Polysaccharide O/F Polyol O/F Other O/F
    L-Arabinose:  neg Fructose:  neg Galactose:  neg Glucose:  neg Mannose:  neg Ribose:  neg D-Tagatose:  neg Lactose:  neg Maltose:  neg Melezitose:  neg Sucrose:  neg Trehalose:  neg Dextrin:  neg Glycogen:  neg D-Arabitol:  neg Mannitol:  neg Sorbitol:  neg
    ENZYME ACTIVITY
    Enzymes: General Enzymes: Carbohydrate Enzymes: Protein Enzymes: Arylamidases Enzymes: Esters/fats
    Urease:  neg Coagulase:  neg Ac-β-glcamnd:  neg α-Fucosidase:  neg α-Galactosidase:  neg β-Galactosidase:  neg α-Glucosidase:  neg β-Glucosidase:  neg β-Glucuronidase:  neg β-Mannosidase:  neg ArgDH:  vr GluDC:  neg AlanineAA:  neg AlaPheProAA:  neg GluGluAA:  neg GlyAA:  vr HisAA:  w LeuAA:  vr LeuGlyAA:  neg ProAA:  neg PheAA:  neg PyrogluAA:  neg AlkalineP:  neg
    METABOLITES - PRODUCTION & USE
    Fuel Usable Metabolites Metabolites Released Special Products Compounds Produced

    		Butyrate:  + Indole:  d(+)
    ANTIBIOTICS ℞
    Penicillins & Penems (μg/mL) Cephalosporins (μg/mL) Aminoglycosides (μg/mL) Macrolides (μg/mL) Quinolones (μg/mL)
    amoxicillin:  S(MIC50): ≤0.125, MIC90: ≤0.5, RNG: (≤0.125-32)
    Augmentin:  S(MIC50): ≤0.125, MIC90: ≤0.5, RNG: (≤0.125-32)
    ampicillin:  S(MIC50): 0.03, MIC90: 0.06, RNG: (0.03-0.125)
    amp-sulb:  S(MIC50): 0.25, MIC90: 0.25, RNG: (0.12-8)
    penicillin:  S(MIC50): 0.06, MIC90: 0.25, RNG: (0.03–0.5)
    penicillin_G:  S(MIC50): 0.03, MIC90: 1, RNG: (0.03-1)
    piper-taz:  S(MIC50): ≤0.03, MIC90: ≤0.03, RNG: (≤0.03-0.06)
    tica-clav:  S(MIC50): 0.5, MIC90: 16, RNG: (0.06–128)
    doripenem:  S(MIC50): ≤0.016, MIC90: 0.03, RNG: (≤0.016-0.125)
    ertapenem:  S(MIC50): 0.125, MIC90: 0.5, RNG: (0.06–4)
    imipenem:  S(MIC50): ≤0.06, MIC90: 0.125, RNG: (≤0.016-2)
    meropenem:  S(MIC50): ≤0.016, MIC90: 0.03, RNG: (≤0.016-0.125)
    cefepime:  S(MIC50): 1, MIC90: 2, RNG: (0.25–32)
    cefoperazone:  S(MIC50): 0.5, MIC90: 2, RNG: (0.06-2)
    cefotaxime:  S(MIC50): 0.25, MIC90: 8, RNG: (0.125-8)
    cefotetan:  S(MIC50): 0.5, MIC90: 1, RNG: (0.25–4)
    cefoxitin:  S(MIC50): 1, MIC90: 1, RNG: (1-8)
    ceftazidime:  Var(MIC50): 2, MIC90: 16, RNG: (0.5-16)
    ceftizoxime:  Var(MIC50): 0.25, MIC90: 32, RNG: (0.062-32)
    cefuroxime:  S(MIC50): 0.25, MIC90: 8, RNG: (0.06–32)
    moxalactam:  S(MIC50): 1, MIC90: 2, RNG: (0.25-2)
    azithromycin:  Var(MIC50): 4, MIC90: >32, RNG: (0.5–>32)
    erythromycin:  Var(MIC50): 4, MIC90: >32, RNG: (1–>32)
    clarithromycin:  S(MIC50): 1, MIC90: >64, RNG: (0.25–>64)
    pristinamycin:  S(MIC50): 0.12, MIC90: 0.12, RNG: (0.03–0.12)
    quin-dalf:  S(MIC50): 0.5, MIC90: 0.5, RNG: (0.25-0.5)
    roxithromycin:  Var(MIC50): 8, MIC90: >32, RNG: (4–>32)
    telithromycin:  S(MIC50): 0.03, MIC90: 0.03, RNG: (0.03)
    linezolid:  S(MIC50): 1, MIC90: 2, RNG: (0.5-2)
    ciprofloxacin:  Var(MIC50): 0.5, MIC90: 8, RNG: (0.12-32)
    gatifloxacin:  S(MIC50): 0.5, MIC90: 2, RNG: (0.125-16.0)
    gemifloxacin:  S(MIC50): 0.125, MIC90: 0.5, RNG: (0.03-0.5
    levofloxacin:  Var(MIC50): 0.5, MIC90: 16, RNG: (0.12-16)
    moxifloxacin:  S(MIC50): 0.25, MIC90: 2, RNG: (0.06-16.0)
    ofloxacin:  Var(MIC50): 0.25, MIC90: 32, RNG: (0.5-32)
    sparfloxacin:  S(MIC50): 0.5, MIC90: 0.5, RNG: (0.125–0.5)
    trovafloxacin:  S(MIC50): 1, MIC90: 1, RNG: (0.5–2)
    Tetracyclines (μg/mL) Vancomycin Class (μg/mL) Polypep/ketides (μg/mL) Heterocycles (μg/mL) Other (μg/mL)
    doxycycline:  S(MIC50): 0.125, MIC90: 4, RNG: (0.06–16)
    minocycline:  S(MIC50): 0.125, MIC90: 8, RNG: (0.03–8)
    tetracycline:  Var(MIC50): 0.5, MIC90: 16, RNG: (0.125–32)
    tigecycline:  S(MIC50): 0.06, MIC90: 0.25, RNG: (0.015–0.25)
    dalbavancin:  S(MIC50): 0.06, MIC90: 0.125, RNG: (0.03–0.25)
    teicoplanin:  S(MIC50): 0.125, MIC90: 0.125, RNG: (0.006-0.25)
    vancomycin:  S(MIC50): 0.5, MIC90: 1, RNG: (0.125-1.0)
    bacitracin:  S(MIC50): 0.25, MIC90: 1, RNG: (0.125–1)
    chloramphenicol:  S(MIC50): 2, MIC90: 4, RNG: (1–8)
    metronidazole:  S(MIC50): 0.5, MIC90: 2, RNG: (≤0.125-2)
    ranbezolid:  S(MIC50): 0.008, MIC90: 0.016, RNG: (0.008-0.03)
    clindamycin:  Var(MIC50): 0.06, MIC90: >16, RNG: (0.06->16)
    daptomycin:  S(MIC50): ≤0.03, MIC90: ≤0.03, RNG: (≤0.03-0.25)

    References

    SPECIFIC REFERENCES FOR PEPTONIPHILUS ASACCHAROLYTICUS
  • Ezaki1983 - Transfer of Peptococcus indolicus, Peptococcus asaccharolyticus, Peptococcus prevotii, and Peptococcus magnus to the Genus Peptostreptococcus and Proposal of Peptostreptococcus tetradius sp. nov.
  • Ezaki2001 - Proposal of the genera Anaerococcus gen. nov., Peptoniphilus gen. nov. and Gallicola gen. nov. for members of the genus Peptostreptococcus.
  • Ezaki2011eBergey - Bergey's manual of systematic bacteriology. Vol. 3, The Firmicutes. Clostridiales, Family XI. Incertae Sedis, Genus VI. Peptoniphilus
  • Goldstein2013 - In vitro activity of Biapenem plus RPX7009, a carbapenem combined with a serine β-lactamase inhibitor, against anaerobic bacteria.
  • Tyrrell2012 - In vitro activity of TD-1792, a multivalent glycopeptide-cephalosporin antibiotic, against 377 strains of anaerobic bacteria and 34 strains of Corynebacterium species.
  • Snydman2008 - In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
  • Goldstein2008 - In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
  • Goldstein2006a - In vitro activity of ceftobiprole against aerobic and anaerobic strains isolated from diabetic foot infections.
  • Goldstein2006b - In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic gram-positive isolates recovered from diabetic foot infections.
  • Goldstein2006c - Comparative in vitro susceptibilities of 396 unusual anaerobic strains to tigecycline and eight other antimicrobial agents.
  • Goldstein2005 - Comparative in vitro activities of XRP 2868, pristinamycin, quinupristin-dalfopristin, vancomycin, daptomycin, linezolid, clarithromycin, telithromycin, clindamycin, and ampicillin against anaerobic gram-positive species, actinomycetes, and lactobacilli.
  • Citron2003 - In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria.
  • Goldstein2003a - In vitro activities of ABT-492, a new fluoroquinolone, against 155 aerobic and 171 anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis.
  • Goldstein2000 - Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens.
  • Goldstein2000a - Comparative In vitro activities of ertapenem (MK-0826) against 1,001 anaerobes isolated from human intra-abdominal infections.
  • Goldstein1999 - In vitro activity of gemifloxacin (SB 265805) against anaerobes.
  • Goldstein1999a - Activity of gatifloxacin compared to those of five other quinolones versus aerobic and anaerobic isolates from skin and soft tissue samples of human and animal bite wound infections.
  • Goldstein1999b - Activities of telithromycin (HMR 3647, RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and other antimicrobial agents against unusual anaerobes.
  • Goldstein1991 - Goldstein EJ, Citron DM. Susceptibility of anaerobic bacteria isolated from intra-abdominal infections to ofloxacin and interaction of ofloxacin with metronidazole.
  • Murdoch1998a - Gram-Positive Anaerobic Cocci.
  • ...............................
    • GUT MICROBIOME COMPILATIONS AND METASTUDIES FOR PEPTONIPHILUS ASACCHAROLYTICUS
  • Benno1986 - Comparison of the fecal microflora in rural Japanese and urban Canadians.
  • Benno1989 - Comparison of fecal microflora of elderly persons in rural and urban areas of Japan.
  • Byrd2020 - Stability and dynamics of the human gut microbiome and its association with systemic immune traits.
  • Finegold1974 - Effect of diet on human fecal flora: comparison of Japanese and American diets
  • Finegold1977 - Fecal microbial flora in Seventh Day Adventist populations and control subjects.
  • Lagier2016 - Culture of previously uncultured members of the human gut microbiota by culturomics.
  • Moore1974 - Human fecal flora: the normal flora of 20 Japanese-Hawaiians.
  • RajilicStojanovic2014 - The first 1000 cultured species of the human gastrointestinal microbiota.
  • ...............................
    • GENERAL REFERENCES FOR PEPTONIPHILUS ASACCHAROLYTICUS
  • Ludwig2009 - Revised road map to the phylum Firmicutes.
    • Added: April 08, 2021